Tolero Pharmaceuticals to Present Progress of Leukemia and Anemia Programs at the 58th ASH Annual Meeting and Exposition

SALT LAKE CITY--()--Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for oncology and hematological diseases, announced today that it will present one oral and one poster presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, December 3 through 6, 2016. The presentations include nonclinical results that further support the development of Tolero’s clinical and preclinical pipeline of agents, including the CDK9 inhibitor (alvocidib) and the ALK2 inhibitor (TP-0184).

Details of the oral presentation are as follows:

Publication Number: #263
Title: The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease
Presenter: Steven L. Warner, Ph.D.
Session Title: 102. Regulation of Iron Metabolism: Hepcidin and the Regulation of Iron Homeostasis
Session Date & Time: Sunday, December 4, 2016, 7:30 AM-9:00 AM PT
Presentation Time: 8:30 AM PT
Location: Manchester Grand Hyatt San Diego, Grand Hall A

Details of the poster presentations are as follows:

Abstract: #1652
Title: Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia
Presenter: Steven L. Warner, Ph.D.
Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 PM-7:30 PM PT
Location: San Diego Convention Center, Hall GH

About Alvocidib

Alvocidib is a potent small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) in development as a combination therapy for frontline and relapsed/refractory AML. CDK9 is a protein critical to the regulation of gene expression including the MCL-1 gene and other important genes involved in cancer. Given the key role CDK9 de-regulation plays in expression of cancer-associated genes related to cell division and proliferation, CDK9 is an attractive target for the treatment of various cancers.

About TP-0184

TP-0184 is a small molecule inhibitor of activin-like kinase 2 (ALK2), also known as a bone morphogenetic protein (BMP) receptor. ALK2 activation leads to high levels of hepcidin, a peptide liver hormone that functions as a master regulator of serum iron levels, particularly in response to inflammation. Anemia of chronic disease (ACD) is a condition where chronic infection, immune activation or cancer lead to high levels of hepcidin via Interleukin-6 production, which reduces iron levels in the blood to low levels. Inhibiting ALK2 with TP-0184 is a unique approach to treating ACD by reducing hepcidin expression and restoring blood iron levels to normal.

About Tolero

Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias, anemia, and solid tumors, as well as important targets of drug resistance and transcriptional control.


Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003

Release Summary

Tolero Pharmaceuticals to present progress of leukemia and anemia programs at the 58th ASH annual meeting and exposition.


Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003